Výsledky vyhledávání - "Scott S, Barker"

Selpercatinib in Patients With

Autor: Alexander, Drilon, Vivek, Subbiah, Oliver, Gautschi, Pascale, Tomasini, Filippo, de Braud, Benjamin J, Solomon, Daniel, Shao-Weng Tan, Guzmán, Alonso, Jürgen, Wolf, Keunchil, Park, Koichi, Goto, Victoria, Soldatenkova, Sylwia, Szymczak, Scott S, Barker, Tarun, Puri, Aimee, Bence Lin, Herbert, Loong, Benjamin, Besse

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41(2)

Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase inhibitor, is currently approved for the treatment of patients withPatients were enrolled to LIBRETTO-001, a phase I/II, single-arm, open-label study of selpercatinib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::765195bda1dd85cefc6dfb87f1c727c7
https://pubmed.ncbi.nlm.nih.gov/36207414

Zobrazit plný text záznamu

Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology

Autor: Lisa M. Hess, Alan Brnabic, Pablo Lee, Oksana Mason, Scott S. Barker

Publikováno v: Journal of Cancer

Introduction: With a gap in a full understanding of the mechanisms by which survival is extended for patients with cancer who are treated with novel biologic and targeted agents, there is the risk that discordant progression-free and overall survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e34eaa9c668046ef8b8037fc1a17134d
http://europepmc.org/articles/PMC6636299

Zobrazit plný text záznamu

Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices

Autor: Scott S. Barker, Eric Nadler, Chuck Wentworth, Thomas Wilson, Pearl Plernjit French, Lisa M. Hess, E. Susan Amirian, Marley Boyd, Kathleen M. Aguilar

Publikováno v: Sarcoma, Vol 2020 (2020)
Sarcoma

Introduction. This study was designed to describe demographic and clinical characteristics of patients diagnosed with advanced or metastatic soft tissue sarcoma (STS) and to examine treatment and healthcare resource utilization patterns of this patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f33a68f9d298cf12861b6252d6988ec
https://doaj.org/article/6add2362eadf47a7ba2212cc08fb486e

Zobrazit plný text záznamu

Incidence and Management of Olaratumab Infusion-Related Reactions

Autor: Samuel Cowan Ramage, Scott S. Barker, Volker Wacheck, Ashwin Shahir, Emily Barrett, William D. Tap, Steven Attia, Brian A. Van Tine, Rangaswamy Govindarajan, Neeta Somaiah, Pablo Lee

Publikováno v: Journal of oncology practice. 15(11)

PURPOSE: Olaratumab is a human monoclonal immunoglobulin G1 antibody against platelet-derived growth factor receptor-α. We report the nature and frequency of infusion-related reactions (IRRs) with olaratumab in clinical trials and postmarketing repo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d691d87b65bdf8eb10a7e6a151eb0f
https://pubmed.ncbi.nlm.nih.gov/31693451

Zobrazit plný text záznamu

Oral selpercatinib in pediatric patients (pts) with advanced RET-altered solid or primary CNS tumors: Preliminary results from the phase 1/2 LIBRETTO-121 trial

Autor: Michela Casanova, Alberto S. Pappo, Daniel A. Morgenstern, Martin Campbell, Catherine M. Albert, Leo Mascarenhas, Scott S. Barker, Theodore W. Laetsch, Karsten Nysom, David S. Ziegler, Jennifer Wright, Meng Xia

Publikováno v: Journal of Clinical Oncology. 39:10009-10009

10009 Background: Activating RET alterations are oncogenic drivers of select pediatric and adult cancers. Selpercatinib is a first-in-class, highly selective and potent, CNS active RET kinase inhibitor. The manageable toxicity profile and durable ant

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8286d8839d7a74af5e7a50516b9e961
https://doi.org/10.1200/jco.2021.39.15_suppl.10009

Zobrazit plný text záznamu

Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non–Small-Cell Lung Cancer

Autor: Joseph Treat, Hossein Borghaei, Coleman K. Obasaju, Scott S. Barker, Thomas E. Stinchcombe

Publikováno v: Clinical Lung Cancer. 17:1-9

Standard platinum-based chemotherapy combinations for advanced non-small-cell lung cancer (NSCLC) have reached a plateau in terms of the survival benefit they offer for patients. In addition, the emerging clinical trend of tailored treatment based on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1335c807f333f2b8ee53fd716959323f
https://doi.org/10.1016/j.cllc.2015.07.002

Zobrazit plný text záznamu

Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies

Autor: Hak Choy, Joseph Treat, David E. Gerber, Coleman K. Obasaju, Matthew J. Monberg, Scott S. Barker, Ramaswamy Govindan, Andrew Koustensis, Puneeth Iyengar, Jeffrey D. Bradley

Publikováno v: Lung cancer (Amsterdam, Netherlands). 87(3)

Current standard for locally advanced non-small cell lung cancer (NSCLC) is combined concurrent therapy with a platinum-based regimen. Preclinical synergistic activity of pemetrexed with radiation therapy (RT) and favorable toxicity profile has led t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc67d8def5ef1d874ad8bf253a3bf582
https://pubmed.ncbi.nlm.nih.gov/25650301

Zobrazit plný text záznamu

Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer

Autor: Joseph Treat, Coleman K. Obasaju, Carla Visseren-Grul, Christian Manegold, George R. Simon, Scott S. Barker

Publikováno v: Clinical lung cancer. 14(6)

Supported by evidence from the LACE (Lung Adjuvant Cisplatin Evaluation) metaanalysis, cisplatin-based adjuvant chemotherapy is now recommended as the standard of care for patients with surgically resected early-stage non-small-cell lung cancer (NSCL

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f1553ba20d73c1eca2a9aed04eb128
https://pubmed.ncbi.nlm.nih.gov/23921171

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání